AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8346498
Drug: Nicotine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (2.0 mg given eight times daily for nine days)
Trial: 8346498
Drug: Histamine challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine challenge after acute doses of nicotine
Trial: 8346498
Drug: Histamine challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine challenge during prolonged treatment with nicotine
Trial: 2940370
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment methods (B regimen)
Trial: 23913968
Drug: Basiliximab/low-dose rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab/low-dose rabbit anti-thymocyte globulin (Bas/rATG)
Trial: 21429514
Drug: Protein-enriched diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-enriched diet (1.1 g protein/100 mL of feeding formula)
Trial: 17006921
Drug: Clonidine (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.075 mg) twice daily for 3 months
Trial: 1545089
Drug: Inhaled gallopamil
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled gallopamil (20 mg)
Trial: 21521379
Drug: Topical triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical triiodothyronine ointment applied twice daily for 12 weeks
Trial: 21521379
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied twice daily for 12 weeks
Trial: 15965585
Drug: Control conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control conditions (non‐intensified vs. intensified therapy, Bobath approach)
Trial: 9673554
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 25 to 30 ml/kg body weight at 37 degrees C infused under the right hemidiaphragm (Group C)
Trial: 9673554
Drug: No peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No peritoneal infusion, no subhepatic drain (Group A)
Trial: 9673554
Drug: No peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No peritoneal infusion but a subhepatic closed drain left for 24 hours (Group B)
Trial: 8079849
Drug: 125 ml
RxNorm normalized name: 125 ML argatroban 1 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 ml of iohexol 350
Trial: 8079849
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml of iohexol 300
Trial: 8079849
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml of diatrizoate meglumine 60%
Trial: 1017281
Drug: New tar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New tar gel
Trial: 25724655
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg or 25 mg
Trial: 22327131
Drug: Palifermin 60
RxNorm normalized name: palifermin
DrugBank: Palifermin (DB00039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Palifermin 60 μg/kg daily for three consecutive days before conditioning and a single dose of 180 μg/kg after conditioning.
Trial: 20337955
Drug: Propofol-ketamine combination
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-ketamine combination
Trial: 23564564
Drug: Peg‐IFN group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFN group (31 patients received Peg‐IFN subcutaneously at a dose of 50 μg per week for 12 months)
Trial: 23564564
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (62 patients followed only, no adjuvant therapies)
Trial: 19393000
Drug: Xolair (anti-IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xolair (anti-IgE treatment) for 16 weeks in patients with high IgE fraction (>3.8%)
Trial: 19393000
Drug: Xolair (anti-IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xolair (anti-IgE treatment) for 16 weeks in patients with low IgE fraction (<1%)
Trial: 16393304
Drug: L. rhamnosus
RxNorm normalized name: L. reuteri/L. rhamnosus 1 billion cell ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. rhamnosus strains (573L/1; 573L/2; 573L/3) administered at a dose of 1.2 x 10(10) CFU, twice daily, for 5 days
Trial: 16393304
Drug: L. rhamnosus
RxNorm normalized name: L. reuteri/L. rhamnosus 1 billion cell ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. rhamnosus strains (573L/1; 573L/2; 573L/3) in rotavirus infection
Trial: 16393304
Drug: L. rhamnosus
RxNorm normalized name: L. reuteri/L. rhamnosus 1 billion cell ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. rhamnosus strains (573L/1; 573L/2; 573L/3)
Trial: 11357896
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg IV
Trial: 11357896
Drug: Azithromycin 250
RxNorm normalized name: azithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 250 mg orally
Trial: 7949622
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy at a dose of 0.7 IU/kg/week (group B)
Trial: 7949622
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy at a dose of 1.4 IU/kg/week (group C)
Trial: 2897559
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g once daily)
Trial: 2897559
Drug: Gentamicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin plus cefuroxime (combination therapy)
Trial: 23704089
Drug: Liposomal daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal daunorubicin (L-DNR)
Trial: 17940996
Drug: Sensitivity and
RxNorm normalized name: STANNOUS FLUORIDE 1.1 mg in 1 g ORAL PASTE [SENSODYNE Sensitivity and Gum Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensitivity and specificity measures in treatment groups
Trial: 11929349
Drug: Triflusal (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal (600 mg/day)
Trial: 10378821
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) (300 mg/day)
Trial: 6638451
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthetic technique of fentanyl and methohexitone
Trial: 30618285
Drug: Theta Burst
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theta Burst Stimulation (TBS) + Physical Therapy (PT)
Trial: 30618285
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Stimulation (FES) + Physical Therapy (PT)
Trial: 30005654
Drug: Combined resistance
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined resistance exercise training guided by a physiotherapist twice a week and increased protein intake under the supervision of a dietitian
Trial: 19114175
Drug: IMVAMUNE (Modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMVAMUNE (Modified Vaccinia Ankara vaccine) followed by Dryvax
Trial: 17686255
Drug: Extended-release metformin
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release metformin 1500 mg qd for 12 weeks
Trial: 17686255
Drug: Glucophage (metformin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucophage (metformin, 500 mg, tid) for 12 weeks
Trial: 1586711
Drug: High-dose rhIL-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rhIL-3
Trial: 363047
Drug: Carbenicillin administered
RxNorm normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbenicillin administered intravenously
Trial: 363047
Drug: Carbenicillin administered
RxNorm normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbenicillin administered intramuscularly
Trial: 28319997
Drug: Single glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single glucocorticoid intradiscal injection (25 mg prednisolone acetate)
Trial: 15067204
Drug: Domperidone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (10 mg per os)
Trial: 15067204
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) (40 mg per os)
Trial: 15067204
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) (40 mg per os) during hyperprolactinemia
Trial: 9663811
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor preparations
Trial: 7820329
Drug: E3810 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E3810 single oral doses (1, 3, 10, 20, 40 and 80 mg) in fasting conditions
Trial: 7820329
Drug: E3810 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E3810 single oral dose (20 mg) after a meal
Trial: 7820329
Drug: E3810 repeated
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E3810 repeated oral doses (20 and 40 mg) once daily for 7 days
Trial: 26100824
Drug: Varenicline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (2 mg single dose)
Trial: 21724872
Drug: Daikenchuto (TJ‐100)
RxNorm normalized name: TJ-CD4B/ABL111
DrugBank: Givastomig (DB18618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daikenchuto (TJ‐100) 5-g administration
Trial: 21724872
Drug: Daikenchuto (TJ‐100)
RxNorm normalized name: TJ-CD4B/ABL111
DrugBank: Givastomig (DB18618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daikenchuto (TJ‐100) 2.5 to 10 g/day
Trial: 15274666
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg daily and tinidazole 500 mg two tablets daily with lansoprazole 30 mg daily for 6 days (ATL-group)
Trial: 10992830
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.3 mg)
Trial: 11071674
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (0.14 mg/kg)
Trial: 11071674
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous and intrathecal)
Trial: 8871173
Drug: Acetazolamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (500 mg) in supplementary experiments
Trial: 1386245
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 8 mg of ondansetron followed by a 24 h infusion of 1 mg h‐1 (group 1)
Trial: 1386245
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 32 mg of ondansetron (group II)
Trial: 1386245
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 8 mg of ondansetron (group III)
Trial: 29314146
Drug: Sofosbuvir (SOF)
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir (SOF) 400 mg + Daclatasvir (DCV) 60 mg daily + weight-based Ribavirin (RBV) for 12 weeks (or 24 weeks if RBV contraindicated)
Trial: 29121974
Drug: Minocycline added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline added to treatment as usual (TAU)
Trial: 29121974
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids added to treatment as usual (TAU)
Trial: 29121974
Drug: Minocycline and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline and/or omega-3 fatty acids added to treatment as usual (TAU)
Trial: 26414968
Drug: Spironolactone (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25-50 mg)
Trial: 10404850
Drug: Immediate-release ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release ranolazine (various dosing regimens)
Trial: 2185298
Drug: Daily paracentesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily paracentesis (3‐4 litre) and intravenous albumin infusion
Trial: 2185298
Drug: Daily paracentesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily paracentesis
Trial: 2185298
Drug: Ascites recirculation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascites recirculation and daily paracentesis
Trial: 7387803
Drug: Calcium chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium chloride (10 ml of a 10% solution, containing elemental calcium 27 mg ml‐1)
Trial: 7387803
Drug: Calcium gluceptate
RxNorm normalized name: Calcium Gluceptate
DrugBank: Calcium glucoheptonate (DB00326)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium gluceptate (20 ml, containing elemental calcium 18 mg ml‐1)
Trial: 30834520
Drug: Concurrent exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent exposure to maternal socioeconomic and psychosocial indicators of adversity
Trial: 30479999
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) delivered by respiratory nurses
Trial: 11463510
Drug: Levetiracetam (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (2000 mg/day)
Trial: 9711471
Drug: Bromazepam 1.5
RxNorm normalized name: bromazepam 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam 1.5 mg
Trial: 30734359
Drug: Case vignettes
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Case vignettes for oral healthcare management
Trial: 23926585
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush (Oral‐B P40®)
Trial: 18541517
Drug: Hypoxia-targeted therapeutics
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxia-targeted therapeutics (e.g., tirapazamine, AQ4N)
Trial: 18541517
Drug: Standard chemotherapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapeutic agents
Trial: 17162245
Drug: UDCA 12-15
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 12-15 mg.kg-1.day-1 with vitamin E 400 IU twice a day (UDCA/Vit E)
Trial: 8725891
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) before radical prostatectomy
Trial: 26958746
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure-lowering therapy (target systolic blood pressure, < 140 mm Hg within 1 hr)
Trial: 26958746
Drug: Guideline-recommended blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended blood pressure-lowering therapy (target systolic blood pressure, < 180 mm Hg)
Trial: 24931951
Drug: 3-drug therapy
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-drug therapy
Trial: 24931951
Drug: monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monotherapy
Trial: 9521221
Drug: Atorvastatin (Lipitor)
RxNorm normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (Lipitor) at dosages of 10 to 80 mg/d
Trial: 7986114
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy of CDDP+VDS
Trial: 7986114
Drug: Surgery +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery + postoperative chemotherapy with CDDP+5‐FU
Trial: 2736615
Drug: Subcutaneous group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous group (I)
Trial: 2736615
Drug: Intradermal group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal group (II)
Trial: 4923653
Drug: L-dopa (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (10 weeks treatment)
Trial: 29208255
Drug: Ice cream
RxNorm normalized name: Nice Cream 2% Topical Dental Foam (mint)
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice cream test
Trial: 18575277
Drug: 75-g OGTT
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75-g OGTT
Trial: 29208255
Drug: Ice cream
RxNorm normalized name: Nice Cream 2% Topical Dental Foam (mint)
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice cream test and 75-g OGTT
Trial: 21223551
Drug: Aspirin (trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (trial medication)
Trial: 12729348
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose of BCG vaccination
Trial: 12729348
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of BCG vaccination
Trial: 9296529
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 3 IU/m2 per day for group 1 (n=6)
Trial: 9296529
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 4.5 IU/m2 per day for group 2 (n=6)
Trial: 9296529
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 3 IU/m2 per day in the 1st year and 4.5 IU/m2 per day thereafter for group 3 (n=5)
Trial: 9296529
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for 4 years (14 children) and 5 years (8 children)
Trial: 8326054
Drug: Behavioral couple
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral couple therapy
Trial: 8326054
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of behavioral couple therapy and cognitive-behavioral therapy
Trial: 19995097
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch (9.5 mg/24 h)
Trial: 20937977
Drug: Lasofoxifene 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasofoxifene 0.5 mg/d
Trial: 20937977
Drug: Lasofoxifene 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasofoxifene 0.25 mg/d
Trial: 16253807
Drug: Endurance-trained subjects;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endurance-trained subjects; Distribution volume of [11C]TMSX in myocardium: 3.6+/‐0.3 ml g(‐1); Triceps brachii muscle: 1.7+/‐0.3 ml g(‐1)
Trial: 16253807
Drug: Untrained subjects;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untrained subjects; Distribution volume of [11C]TMSX in myocardium: 3.1+/‐0.4 ml g(‐1); Triceps brachii muscle: 1.2+/‐0.2 ml g(‐1)
Trial: 1694294
Drug: Aspartame (34
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (34 mg/kg)
Trial: 1694294
Drug: Sucrose (1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (1.75 g/kg)
Trial: 1694294
Drug: Aspartame (9.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (9.7 mg/kg)
Trial: 31924158
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice with cyclosporine (100 mg cyclosporine + 500 ml pomegranate juice)
Trial: 31924158
Drug: Water with
RxNorm normalized name: sterile water with electrolytes injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water with cyclosporine (100 mg cyclosporine + 500 ml water)
Trial: 29619799
Drug: Low-carbohydrate, ketogenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate, ketogenic diet (LC; <50 g/day and <10% of energy from carbohydrates)
Trial: 29619799
Drug: High-carbohydrate diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-carbohydrate diet (HC; 6-10 g/kg/day carbohydrate)